trending Market Intelligence /marketintelligence/en/news-insights/trending/QCdy-Rlq3x6RIjE2HiKNOA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Ionis to undertake $507.5M debt placement in exchange, new issuance offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Ionis to undertake $507.5M debt placement in exchange, new issuance offering

Ionis Pharmaceuticals Inc. is undertaking a private placement of $507.5 million of 0.125% convertible senior notes due 2024.

Under the agreements, the Carlsbad, Calif.-based biotechnology company will issue $398 million of 0.125% convertible senior notes due 2024 in exchange for its outstanding $340.2 million of 1.00% convertible senior notes due 2021.

Following the closing of the exchange offer, $344.8 million of 1.00% convertible senior notes due 2021 will remain outstanding.

Ionis said in a Dec. 12 press release that it will not receive any cash proceeds from the exchange transactions.

In addition, Ionis will issue $109.5 million of 0.125% convertible senior notes due 2024 for cash and expects to raise about $99.2 million in net proceeds from the transaction.

Ionis plans to use the net cash proceeds to pay costs associated with a convertible note hedge and warrant transactions, which it has entered into with several financial institutions related to the current private placement.

The funds will also be used for general corporate purposes.